Scandion Oncology A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 4
- Market Cap
- -
Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Scandion Oncology A/S
- Target Recruit Count
- 18
- Registration Number
- NCT04652206
- Locations
- 🇩🇰
Aalborg University Hospital, Aalborg, Denmark
🇩🇰Odense Universitetshospital, Odense, Denmark
🇩🇪Catholic Hospital Bochum - St. Josef-Hospital, Bochum, Germany
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Scandion Oncology A/S
- Target Recruit Count
- 35
- Registration Number
- NCT04247256
- Locations
- 🇩🇰
Vejle Sygehus, Vejle, Denmark
🇩🇪Charité, Berlin, Germany
🇩🇪Catholic Hospital Bochum - St. Josef-Hospital, Bochum, Germany
© Copyright 2024. All Rights Reserved by MedPath